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Abstract
Background: While the patient and public involvement (PPI) evidence base has
expanded over the past decade, the quality of reporting within papers is often
inconsistent, limiting our understanding of how it works, in what context, for whom,
and why.
Objective: To develop international consensus on the key items to report to enhance
the quality, transparency, and consistency of the PPI evidence base. To collaboratively
involve patients as research partners at all stages in the development of GRIPP2.
Methods: The EQUATOR method for developing reporting guidelines was used. The
original GRIPP (Guidance for Reporting Involvement of Patients and the Public)
checklist was revised, based on updated systematic review evidence. A three round
Delphi survey was used to develop consensus on items to be included in the
guideline. A subsequent face-to-face meeting produced agreement on items not
reaching consensus during the Delphi process.
Results: One hundred forty-three participants agreed to participate in round one,
with an 86% (123/143) response for round two and a 78% (112/143) response for
round three. The Delphi survey identified the need for long form (LF) and short form
(SF) versions. GRIPP2-LF includes 34 items on aims, definitions, concepts and theory,
methods, stages and nature of involvement, context, capture or measurement of
impact, outcomes, economic assessment, and reflections and is suitable for studies
where the main focus is PPI. GRIPP2-SF includes five items on aims, methods, results,
outcomes, and critical perspective and is suitable for studies where PPI is a secondary
focus.
Conclusions: GRIPP2-LF and GRIPP2-SF represent the first international evidence based,
consensus informed guidance for reporting patient and public involvement in research.
Both versions of GRIPP2 aim to improve the quality, transparency, and consistency of
the international PPI evidence base, to ensure PPI practice is based on the best
evidence. In order to encourage its wide dissemination this article is freely accessible
on The BMJ and Research Involvement and Engagement journal websites.
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Background
The EQUATOR network has developed high standard reporting guidelines such as the
CONSORT (Consolidated standards of Reporting Trials) statement and the STROBE
(Strengthening the Reporting of Observational Studies in Epidemiology) statement
enhancing the quality of research reporting, but no guidance has been developed specifically
for the reporting of patient and public involvement (PPI). This prompted the development
of the original Guidance for Reporting Involvement of Patients and the Public (GRIPP),
which tackled inconsistent reporting by helping researchers, patients, carers, and the public
to improve the quality, consistency, and transparency of PPI reporting, to strengthen the
quality of the international PPI evidence base [1]. While the original GRIPP checklist repre-
sented an important starting point in creating high quality PPI reporting, its development
drew on systematic review evidence, without broader input from the international PPI re-
search community [2–4]. Achieving consensus is now acknowledged as a crucial step in
producing a reporting guideline [5]. GRIPP2 tackled this gap by developing consensus in
the international PPI community.
INVOLVE defines public involvement in research as being carried out with or by mem-
bers of the public rather than to, about, or for them. PPI in research can improve the rele-
vance and overall quality of research, by ensuring that it focuses on the issues of importance
to patients [1]. This includes, for example, working with research funders to prioritise re-
search; the development of more patient relevant research questions, study designs, and
outcomes; offering the patient perspective as members of a project steering group; com-
menting on and developing research materials to improve readability; assisting with recruit-
ment to studies; lay write up of the studies; and advocacy of study results [2–4, 6–9]. In the
UK, the National Institute for Health Research has provided vital strategic and infrastruc-
ture support to embed PPI across publicly funded research, creating a context where PPI is
Plain English summary
Patient and public involvement in health and social care research is increasingly important, helping
to ensure that the research focuses on issues relevant to patients and the public. A wide variety of
research papers with public involvement has been published over the past decade, yet many of these
papers give little information about how members of the public were involved and what the result of
this involvement was. This means that learning from these studies is limited. Working closely with
patients and the public, we have developed guidance for people writing about public involvement to
suggest what details to report. We carried out a thorough assessment of studies in this area and used a
Delphi survey to ask 143 people who are knowledgeable about this topic for their opinions about what
should be included in the guidance. The Delphi method consists of a series of questionnaires over a
specific time period to find out whether there is agreement among experts about the topic under
discussion. We found strong agreement on a number of issues to include in the guidance from the 112
people who completed three rounds of Delphi questionnaires. We also held a one day meeting to find
out whether any additional issues for which we hadn’t reached agreement should be included in the
guidance.
As a result of this three stage project, we developed two versions of the guidance, a short version of
the guidance (GRIPP2-SF), which can be used when reporting public involvement in any study, and a
long version (GRIPP2-LF) to use when the study is mainly about public involvement in research. Our
aim in developing this guidance is to promote good quality reporting of public involvement, to
inform good practice and create effective public involvement.
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seen as a key element in research. Internationally PPI is also developing, with similar initia-
tives in Canada, United States, Australia, and Europe [10, 11]. Networks such as the citizen
and patient involvement group of Health Technology International have evolved, enabling
international collaboration in relation to involvement and engagement [12].
While the PPI evidence base has expanded significantly over the past decade, the
reporting of PPI in papers has often been inconsistent and partial, with little informa-
tion about the context, process, and impact of public involvement and with limited
reporting of conceptualisation or theorisation [1–4]. Inadequate reporting can create
problems for systematic reviews that attempt to synthesise PPI evidence [2–4]. Ap-
praisal, interpretation, and synthesis of results are difficult, aside from the ethical im-
peratives of reporting research in a way that others understand and can use [13–16].
Inconsistent reporting creates a fragmented evidence base making it difficult to draw
together our collective understanding of what works, for whom, why, and in what
context. Furthermore, researchers, patients, carers, or clinicians cannot learn from
previous experience, and precious resources devoted to involving patients and the
public are wasted. Omitting descriptions of PPI activities from a study can represent a
form of misreporting and might misrepresent the initial intentions of a study.
This article introduces the two versions of the GRIPP2 reporting checklist: GRIPP2-LF, a
longer checklist for studies where PPI forms the primary focus of a study (Table 1) and
GRIPP2-SF, a short checklist for studies where PPI is a secondary or tertiary focus (Table 2).
We also describe the development of GRIPP2 and outline how it can be used.
GRIPP2 reporting checklist development methods
The study used the EQUATOR method for developing reporting guidelines [5], which in-
cluded: systematic review evidence; a three stage Delphi survey including key stakeholders
in the field of PPI; and a face-to-face collaborative meeting to develop consensus on items
outstanding from the Delphi survey. A summary of methods is presented, with a compan-
ion paper reporting the rationale for GRIPP2 and the full methods [17]. For the purposes
of this paper, we have therefore reported only a summary of key steps in Appendix 1.
The systematic reviews that underpinned the original GRIPP checklist had already iden-
tified the need for the guidance [2–4]. The PIRICOM systematic review, which included
the conceptualisation, definition, measurement, impact, and outcomes of PPI on research,
researchers, service users, participants, funders, and policy makers, was updated for
GRIPP2 to ensure no additional concepts were omitted from the Delphi survey. In
addition, searches were conducted to identify any other reporting guidelines for PPI.
Three rounds of the Delphi survey were conducted to gain consensus (see Appendix 2).
This included 143 international participants in round one, with an 86% (123/143) re-
sponse for round two and a 78% (112/143) response for round three reflecting the stand-
ard number of participants used in the development of previous EQUATOR guidance [5].
Participants of the Delphi survey included researchers, funders, patients, carers, editors,
and individuals from international research agencies from countries including Australia,
the United States, Canada, and Europe. Collectively, participants represented a wide range
of expertise relevant to the development of consensus in PPI reporting.
Participants were asked to rate each item in the checklist on a scale of 1–10, with 1
considered unimportant and 10 considered very important, and medians and interquartile
ranges were calculated for each item in the Delphi survey. Space next to each item was
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Table 1 GRIPP2 long form
Section and topic Item Reported
on page
No
Section 1: Abstract of paper
1a: Aim Report the aim of the study
1b: Methods Describe the methods used by which patients and the
public were involved
1c: Results Report the impacts and outcomes of PPI in the study
1d:Conclusions Summarise the main conclusions of the study
1e: Keywords Include PPI, “patient and public involvement,” or alternative
terms as keywords
Section 2: Background to paper
2a: Definition Report the definition of PPI used in the study and how it
links to comparable studies
2b: Theoretical
underpinnings
Report the theoretical rationale and any theoretical
influences relating to PPI in the study
2c: Concepts and
theory development
Report any conceptual or theoretical models, or influences,
used in the study
Section 3: Aims of paper
3: Aim Report the aim of the study
Section 4: Methods of paper
4a: Design Provide a clear description of methods by which patients
and the public were involved
4b: People involved Provide a description of patients, carers, and the public
involved with the PPI activity in the study
4c: Stages of involvement Report on how PPI is used at different stages of the study
4d: Level or nature of
involvement
Report the level or nature of PPI used at various stages
of the study
Section 5: Capture or measurement of PPI impact
5a: Qualitative evidence
of impact
If applicable, report the methods used to qualitatively
explore the impact of PPI in the study
5b: Quantitative evidence
of impact
If applicable, report the methods used to quantitatively
measure or assess the impact of PPI
5c: Robustness of
measure
If applicable, report the rigour of the method used to
capture or measure the impact of PPI
Section 6: Economic assessment
6: Economic assessment If applicable, report the method used for an economic
assessment of PPI
Section 7: Study results
7a: Outcomes of PPI Report the results of PPI in the study, including both
positive and negative outcomes
7b: Impacts of PPI Report the positive and negative impacts that PPI has
had on the research, the individuals involved (including
patients and researchers), and wider impacts
7c: Context of PPI Report the influence of any contextual factors that
enabled or hindered the process or impact of PPI
7d: Process of PPI Report the influence of any process factors, that
enabled or hindered the impact of PPI
7ei: Theory development Report any conceptual or theoretical development in
PPI that have emerged
7eii: Theory development Report evaluation of theoretical models, if any
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used for free text comments with suggested refinements, reiterations, and additional items.
If items reached a median score of ≥8 in round one and round two they were considered
to have reached positive consensus and included. Items that reached a median ≤ 5 in
rounds one and two were excluded from the checklist. Items that reached a medium score
of 6 or 7 in one round and a median score of ≥8 in the other round were voted on again in
round three. Positive consensus was gained if the items scored a median score of ≥8 in two
of the rounds. An important finding from the first round was that participants thought
GRIPP items were most relevant when the main focus of a study was on PPI, and many felt
there should be a shorter version for papers that included some element of PPI. As a result
participants were asked to identify and score “core” items in round two which could be in-
cluded in a shortened version of the guideline, suitable for studies that have included PPI
as a secondary focus. The five core items that comprise the GRIPP2-SF all gained a median
score of 9 in round two. Thus all five were included in round three and again gained me-
dian scores of 9, indicating that consensus was reached on the short form version.
Table 1 GRIPP2 long form (Continued)
7f: Measurement If applicable, report all aspects of instrument development
and testing (eg, validity, reliability, feasibility, acceptability,
responsiveness, interpretability, appropriateness, precision)
7 g: Economic assessment Report any information on the costs or benefit of PPI
Section 8: Discussion and conclusions
8a: Outcomes Comment on how PPI influenced the study overall. Describe
positive and negative effects
8b: Impacts Comment on the different impacts of PPI identified in this
study and how they contribute to new knowledge
8c: Definition Comment on the definition of PPI used (reported in the
Background section) and whether or not you would
suggest any changes
8d: Theoretical
underpinnings
Comment on any way your study adds to the theoretical
development of PPI
8e: Context Comment on how context factors influenced PPI in the study
8f: Process Comment on how process factors influenced PPI in the study
8 g: Measurement and
capture of PPI impact
If applicable, comment on how well PPI impact was evaluated
or measured in the study
8 h: Economic assessment If applicable, discuss any aspects of the economic cost or benefit
of PPI, particularly any suggestions for future economic modelling.
8i: Reflections/critical
perspective
Comment critically on the study, reflecting on the things that went
well and those that did not, so that others can learn from this study
PPI patient and public involvement
Table 2 GRIPP2 short form
Section and topic Item Reported on
page No
1: Aim Report the aim of PPI in the study
2: Methods Provide a clear description of the methods used for PPI in the study
3: Study results Outcomes—Report the results of PPI in the study, including both positive
and negative outcomes
4: Discussion and
conclusions
Outcomes—Comment on the extent to which PPI influenced the study
overall. Describe positive and negative effects
5: Reflections/critical
perspective
Comment critically on the study, reflecting on the things that went well
and those that did not, so others can learn from this experience
PPI patient and public involvement
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Qualitative comments were analysed thematically to identify common themes, points
of feedback, challenges to the items, and queries about wording [18]. Qualitative com-
ments suggested the need to reword some items to simplify them and ensure clarity
of meaning. Two sections from the original GRIPP checklist, section 5, which focused
on measurement, and section 6, which was focused on capture of impact, were com-
bined as it was recognised that they were conceptually overlapping. The original sec-
tion 8 was deleted as participants thought it duplicated existing items.
Appendices 3 and 4 report the results of the Delphi survey. Following the Delphi
survey, a collaborative consensus meeting was held with 25 key experts with know-
ledge, experience, or both, of PPI, including patient partners and carers (n = 8), re-
searchers (n = 9), clinicians (n = 6), and healthcare journal editors (n = 2). The aim of
this meeting was to finalise consensus on the seven items on the threshold of consen-
sus following the Delphi survey (Appendix 2) and ensure clarity of the items.
Patient partners were collaboratively involved at key stages of the study. Three patient
partners were recruited to the research team and were involved in refining the focus of
the research questions, in development of the search strategy and interpretation of results
of the systematic review, in discussions identifying the need for development of guidelines,
and in selecting the items for the original GRIPP checklist. Furthermore, the patient part-
ners assisted in developing the electronic survey for the first phase of the Delphi survey
consensus process and were instrumental in assisting in recruitment to the Delphi study
and in collation of comments from each Delphi survey round, and contributed to adapt-
ing items for GRIPP2. The consensus meeting involved eight patient partners in total, and
the three patient partners recruited to the research team were involved in the write-up of
the study and are coauthors in papers. More detailed information of their contribution to
the development of GRIPP is described using GRIPP2-SF in Table 3 and used to populate
the BMJ PPI guidance in Table 4.
Scope and illustration of use
GRIPP2-LF (Table 1) and GRIPP2-SF (Table 2) are the first international, evidence
based, community consensus informed guidelines for the reporting of PPI in research.
The checklists provide key PPI concepts that authors should report in papers, to en-
hance the overall quality and transparency of the PPI evidence base. GRIPP2-LF and
GRIPP2-SF ultimately aspire to guide PPI reporting in different types of studies, from
reporting on PPI in trials (GRIPP2-SF) to reporting of PPI focused studies (GRIPP2-
LF). Researchers can use the reporting guideline prospectively to plan PPI in studies
and retrospectively as a quality assurance step in the writing up of PPI in publications
and reports. Health and social care research funders and research institutions could
promote adherence to the GRIPP2 reporting checklist as a means to optimise the creation
of transparent, consistent, and high quality PPI evidence. Journal editors could use
GRIPP2 reporting checklists to set their reporting expectations for submitted manu-
scripts. Higher quality reporting will gradually lead to the development of a stronger
PPI evidence base that will facilitate more effective synthesis of PPI studies.
GRIPP2 can be used in different ways within a paper. For GRIPP 2-LF the entire
paper can be shaped by the guidance, with researchers selecting the items of relevance.
With GRIPP2-SF researchers could present all the information in the body of the paper
under the relevant reporting titles or in a separate box. Table 3 provides an illustration
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Table 3 PPI in the development of GRIPP2 using GRIPP 2-SFa
Section and topic Item
1: Aim
Report the aim of the study
To develop international consensus on the key items to report to
enhance the quality, transparency, and consistency of the PPI
evidence base. To collaboratively involve patients as research
partners at all stages in the development of GRIPP2
2: Methods
Provide a clear description of the
methods used for PPI in the study
Three patient partners were recruited to the research team to
assist at all stages of the development of and consensus process
for the GRIPP2 guidelines. They were involved in refining the focus
of the research questions, in developing the search strategy, in
interpreting results, in discussions identifying the need for
development of guidelines, and in selecting the items for the
original GRIPP checklist. The patient partners helped recruit
participants (n = 60/143) to the Delphi survey through snowballing
techniques. They helped pilot the electronic survey for the first
phase of the Delphi survey consensus process and helped other
patient reps with technical aspects of completing the online
survey, hence improving the response rate in each round of the
Delphi. They also worked with the researchers to collate
comments from each Delphi survey round, to adapt items, and to
feed back to the participants for the next Delphi survey round.
They checked comprehension of changed items and comments
from the lay perspective. The patient partners took part in the
consensus workshop, alongside five other patients (n = 8/25 in
total) to agree consensus on items not reaching consensus and to
adapt wording where items were not clear. The patient partners
contributed to edits of the paper and are coauthors.
3: Results
Outcomes—Report the results of
PPI in the study, including both
positive and negative outcomes
PPI contributed to the study in several ways, including:
- Collating initial evidence
- Identifying items for the GRIPP checklist
- Considering the evidence and their wider experience—the
patients highlighted the importance of including items referring
to the context and processes of PPI, suggesting that this affected
the impact that PPI had on research
- The patient partners, along with other patient organisations and
charities, recruited nearly half of all participants for the Delphi
survey
- The patient partners helped other patients with the technical
aspects of completing the online survey, improving the response
rate in each Delphi survey round.
- The patient partners checked the comprehension of the changed
items and comments from the lay perspective between rounds
and were integral to helping the researchers keep to the
scheduled time of the Delphi survey
- Throughout the write-up phase for both the results paper and
the methods paper the patient partners contributed to the lay
sections and contributed to edits of the paper
4: Discussion
Outcomes—Comment on the extent to
which PPI influenced the study overall.
Describe positive and negative effects
Patient and public involvement in this study was very effective
and influenced important aspects of the study, based on the
impacts in section 3. This might have been related to several
factors. Firstly the patient partners had received training around
research methods in previous studies, and were actively involved
in a patient and public involvement group attached to the
University of Warwick. In addition, the researchers were experienced
at involving patient partners in their research.
The right processes were in place, as the patient partners were
involved from the beginning of the study allowing them to help
shape the study from the start allowing them to contribute fully to
the study. Having the right context, with a collaborative research
team, funding to finance their time, and a supportive attitude of
their involvement from EQUATOR and other collaborators, also
assisted in the positive impact that PPI had on this study. Pre-
existing relationships with patient partners and patients who
attended the collaborative consensus event provided a vital
context for embedded PPI.
However, there were limitations. The methods used to gain
consensus had been developed and tested for reliability and
validity by EQUATOR in the development of previous guidelines,
which limited the possible input from the patient partners in
Staniszewska et al. Research Involvement and Engagement  (2017) 3:13 Page 7 of 11
of GRIPP2 –SF using this study as an example. This table is an illustration of the po-
tential of GRIPP2 reporting. It is purposefully long to demonstrate the type of infor-
mation it could include. A more specific, shorter form of reporting would also be
acceptable, as long as it contained the key information.
Availability
GRIPP2-SF and GRIPP2-LF are available on the EQUATOR webpage (www.equator-
network.org/), or at http://www2.warwick.ac.uk/fac/med/research/hscience/wrn/
research/themea.
Discussion and limitations
GRIPP2-LF and GRIPP2-SF are the first international, evidence based, community consen-
sus informed guidelines for the reporting of patient and public involvement in research.
Although consensus was achieved in the development of GRIPP2, further refinements are
expected over time as the evidence base underpinning PPI evolves, reflecting the iterative
EQUATOR method of guideline development. In addition, it has not yet been possible to
conduct any usability testing to understand how GRIPP2 works in practice with different
types of study designs. The final consensus meeting did not include international experts
because of a restricted budget, which might have limited the discussion from an inter-
national perspective. Thus, the next phase of development for GRIPP2-LF and GRIPP2-SF
should include wider international application and piloting to test conceptual equivalence
in different country contexts. Feedback from researchers using GRIPP2 will help refine it.
We have created a comment box on the Warwick Medical School website to facilitate this
http://www2.warwick.ac.uk/fac/med/research/hscience/wrn/research/themea.
Guidelines such as the CONSORT statement for randomised controlled trials (RCTs)
are regularly updated to reflect changes in health research more widely [19]. Such evolu-
tion is particularly important for GRIPP2 because PPI is at a pre-paradigm stage in its de-
velopment and recognition, reflecting Kuhn’s conceptualisation of how science changes
over time with significant paradigm shifts that generate new ways of thinking [20].
While GRIPP2-LF and GRIPP2-SF aim to guide consistent reporting, it is not possible
to be prescriptive about the exact content of each item, as the current evidence base is
Table 3 PPI in the development of GRIPP2 using GRIPP 2-SFa (Continued)
identifying or developing methods to gain consensus on GRIPP2.
Furthermore, the time for feedback between Delphi survey rounds
was short, and organising times where both researchers and
patient partners could meet was difficult. In similar future studies,
scheduling of these meetings in advance of the Delphi survey
might overcome this limitation.
5: Reflections
Critical perspective—Comment critically
on the study, reflecting on the things
that went well and those that did not,
so others can learn from this experience
The PPI in the study was embedded as far as possible into the
methods for developing consensus. While not a formal part of
EQUATOR methodology, the aim of active collaboration in an
attempt to co-produce knowledge worked well. The key challenge
was the timescales required to ensure the Delphi survey was
completed with appropriate intervals. If this was repeated, these
time scales would require extension. We are aware that this
process might have limited the extent to which patient partners
were able to identify concepts of importance that sit outside of
the traditional research paradigm and so may require further
development in the future.
aAn example of using the long form can be obtained from the authors
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not advanced enough to make this possible [2–4, 21]. Authors should carefully consider
the relevance of each GRIPP2 item but recognise that it is sometimes not necessary,
or even possible, to include each item in a particular manuscript. With future devel-
opment of the evidence base, it will be possible to refine GRIPP items, and some may
become mandatory.
The success of the PPI in this study may relate to several factors. Firstly, the patient
partners had received training around research methods in previous studies and were
actively involved in a patient and public involvement group attached to the University
of Warwick Medical School. Furthermore, the researchers were experienced at involving
patient partners in their research [22]. Finally, good relationships and ways of working
were established, which are known as key factors for facilitating high quality PPI [4, 21].
We recognise that GRIPP2 was developed with experts familiar with PPI and that there
are still significant challenges in academic culture in enacting the behaviour changes that
public involvement requires. PPI needs to become embedded practice within research
rather than an option, and both researchers and patients need to recognise their own
training and development needs, drawing on the evidence base to guide effective practice.
A further limitation is that GRIPP2-LF and GRIPP2-SF are conceptualised within the
culture and language of research. Bearing in mind that the ultimate intention of high
quality reporting in PPI is to develop best practice, there is a need to develop a patient
or service user version of GRIPP2 to ensure comprehensibility and usefulness and to
ensure that patient important concepts indicative of high quality research are included,
although these are yet to be identified. This would reflect important changes in academic
publishing, where patients are regularly writing and peer reviewing academic papers and
require ways of understanding reporting quality [22]. Used alongside other EQUATOR
guidance, the intention is to guide the development of a transparent, consistent, and high
quality PPI evidence base. More effective synthesis of the PPI evidence base will help to
identify best practice, avoid poor practice, and contribute to research that is acceptable,
relevant, appropriate, and high quality and that has the potential to generate benefit for all.
Table 4 Patient and public involvement in GRIPP2 according to BMJ guidance
How was the development of the research question and outcome measures informed by patients’ priorities,
experience, and preferences?
Patients were involved in the original systemic review that underpinned GRIPP and actively contributed to
identifying the issue of inconsistent reporting, the need for guidance, and the research question.
How did you involve patients in the design of this study?
Patients were involved as research partners in all aspects of the study including identifying the original research
question, identifying the need for the original systematic review, and identifying the need for consensus.
Were patients involved in the recruitment to and conduct of the study?
The patient partners, along with other patient organisations and charities, recruited nearly half of all
participants for the Delphi survey. They helped pilot the electronic survey for the first phase of the Delphi
survey consensus process and helped other patient reps with technical aspects of completing the online
survey, hence improving the response rate in each round of the Delphi. They also worked with the researchers
to collate comments from each Delphi survey round, to adapt items, and to feed back to the participants for
the next Delphi survey round. They checked comprehension of changed items and comments from the lay
perspective. The patient partners took part in the consensus workshop, alongside five other patients (n = 8/25 in
total) to agree consensus on items not reaching consensus and to adapt wording where items were not clear.
The patient partners contributed to edits of the paper and are coauthors.
How will the results be disseminated to study participants?
GRIPP2 will be disseminated to all study participants via email. The authors will disseminate via conference
presentations. Funding bodies and other journal editors internationally will be encouraged to use GRIPP2.
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